CVRXHIGH SIGNALFINANCIAL10-K

CVRX experienced severe financial deterioration with stockholders' equity plummeting 45% and cash reserves declining 29% while interest expense exploded nearly 1000%.

The dramatic erosion in stockholders' equity combined with the massive spike in interest expense suggests the company has taken on significant debt financing, likely due to cash burn pressures. Despite improved gross margins and reduced operating losses, the overall financial position has weakened substantially, raising concerns about the company's capital structure and financing sustainability.

Comparing 2026-02-13 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

CVRX showed mixed operational performance with gross profit growing 12.5% and operating losses improving 14% to -$51.3M, indicating better operational efficiency. However, the financial structure deteriorated dramatically as stockholders' equity crashed 45% to $39.3M, cash declined 29% to $75.7M, and interest expense exploded 990% to $1.8M, suggesting the company has relied heavily on debt financing to fund operations. The overall picture signals a company making operational progress but facing severe balance sheet stress that threatens long-term viability without additional equity financing or dramatic improvement in cash generation.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+990.3%
$165K$1.8M

Interest expense surged 990.3% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-57.4%
$1.4M$580K

Capex reduced 57.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-44.7%
$71.1M$39.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-28.5%
$105.9M$75.7M

Cash decreased 28.5% — monitor burn rate and upcoming capital needs.

Current Liabilities
Balance Sheet
+23.7%
$10.8M$13.3M

Current liabilities rose 23.7% — increased short-term obligations, watch current ratio.

Current Assets
Balance Sheet
-21.7%
$129.8M$101.6M

Current assets declined 21.7% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-21.5%
$133.4M$104.8M

Total assets contracted 21.5% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+15.1%
$9.3M$10.7M

Receivables grew 15.1% — monitor days sales outstanding for collection efficiency.

Operating Income
P&L
+13.8%
-$59.5M-$51.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Gross Profit
P&L
+12.5%
$43.0M$48.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-18
ADDED
As of February 6, 2026, there were 26,311,607 shares of the registrant s common stock, par value $0.01 per share outstanding.
We estimate our total market opportunity using both prevalence and incidence epidemiologic models in which prevalence reflects the total number of individuals indicated for therapy at a given time, while incidence captures the annual occurrence of new cases meeting the indication.
Based on these distinct models, we estimate that our prevalence-based market opportunity for HFrEF is $10.5 billion in the U.S.
Using an incidence-based model, we estimate an annual market opportunity of $2.4 billion in the U.S.
We currently believe, using a prevalence-based epidemiologic model, our market opportunity in the U.S.
+7 more — sign up free →
REMOVED
As of February 11, 2025, there were 26,036,032 shares of the registrant s common stock, par value $0.01 per share outstanding.
We estimate that our annual market opportunity for HFrEF is $2.2 billion in the U.S.
and $2.8 billion in select European Markets (Germany, France, Italy, Spain, and the United Kingdom, or European Five ).
We currently believe our annual market opportunity in the U.S.
is an estimated $2.2 billion, or 76,000 patients, based on this new long-term safety and effectiveness data as well as our commercial experience and, as discussed below, the new reimbursement assignment for Barostim in 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →